Mylan and Biocon file biosimilar of white blood cell booster
An innovative programme is being rolled out across Kenya.
Applying the right principles results in compelling and valuable segmentation.
10/03/2017February 8, 2017
02/11/2016November 1, 2016
22/11/2016October 20, 2016
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.
A new whitepaper presenting analysis of exclusive M3 (EU) data, revealing the digital and technological habits and preferences of doctors and how pharma can best engage.